Stock Events

Stock Events

Search...

Odonate

$150,000

18

+$0+0% Tuesday 16:27

Statistics

Day High

150,000

Day Low

150,000

52W High

150,000

52W Low

50,000

Volume

1

Avg. Volume

0

Mkt Cap

2.25B

P/E Ratio

7.29

Dividend Yield

-

Dividend

-

Earnings

25FebExpected

Q1 2022

Q2 2022

Q3 2022

Q1 2024

Q2 2024

Q3 2024

Q4 2024

-2,400

-1,600

-800

0

Expected EPS

N/A

Actual EPS

N/A

Financials

-Profit Margin

Profitable

2017

2018

2019

2020

2021

2022

0Revenue

85.88MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ODTC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is a global pharmaceutical company that develops a wide range of medications, including those for cancer treatment, directly competing with Odonate's focus on cancer therapeutics.

Novartis is a multinational pharmaceutical company that produces drugs across a variety of therapeutic areas, including oncology, making it a competitor in the cancer treatment market.

Merck is known for its strong presence in the oncology market, developing treatments that could compete with Odonate's cancer therapies.

Bristol-Myers Squibb

Bristol Myers Squibb is a biopharmaceutical company with a significant focus on cancer drugs, positioning it as a competitor to Odonate Therapeutics.

Roche Holding AG, through its pharmaceuticals division, develops cancer treatments, making it a direct competitor in the oncology sector.

AstraZeneca operates in various therapeutic areas, including oncology, and its development of cancer treatments competes with Odonate's offerings.

Gilead Sciences

Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics, including for cancer, competing with Odonate's cancer focus.

Amgen focuses on human therapeutics, including oncology, which puts it in direct competition with Odonate Therapeutics in the cancer treatment market.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is engaged in the development of medicines for serious medical conditions, including cancer, making it a competitor.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries is a global company that manufactures generic and specialty medicines, including oncology products, competing in the same market as Odonate.

About

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

Show more...

CEO

Mr. Kevin C. Tang

Employees

137

Country

US

ISIN

US6760794031

Listings

0 Comments

Share your thoughts

FAQ

What is Odonate stock price today?▼

The current price of ODTC is $150,000 USD — it has increased by +0% in the past 24 hours. Watch Odonate stock price performance more closely on the chart.

What is Odonate stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Odonate stocks are traded under the ticker ODTC.

What is Odonate market cap?▼

Today Odonate has the market capitalization of 2.25B

What is Odonate revenue for the last year?▼

Odonate revenue for the last year amounts to 0 USD.

What is Odonate net income for the last year?▼

ODTC net income for the last year is 85.88M USD.

How many employees does Odonate have?▼

As of April 01, 2026, the company has 137 employees.

In which sector is Odonate located?▼

Odonate operates in the Financials sector.

When did Odonate complete a stock split?▼

The last stock split for Odonate was on January 15, 2025 with a ratio of 1:8.

Where is Odonate headquartered?▼

Odonate is headquartered in New York, US.